Kara Laing

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

Nanoparticle Delivery of miR-708 Mimetic Impairs Breast Cancer Metastasis

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients

Breast cancer

Triple-negative breast cancer molecular subtyping and treatment progress

Engineering precision nanoparticles for drug delivery

Breast cancer

Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study

Ruthenium Polypyridyl Complex Inhibits Growth and Metastasis of Breast Cancer Cells by Suppressing FAK signaling with Enhancement of TRAIL-induced Apoptosis

Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study

Controlled drug delivery vehicles for cancer treatment and their performance

Cardiovascular toxicity caused by cancer treatment: strategies for early detection

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy

Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer

Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model

Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary

Integration of photothermal therapy and synergistic chemotherapy by a porphyrin self-assembled micelle confers chemosensitivity in triple-negative breast cancer

Neutrophils in cancer: neutral no more

Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ

The use of paclitaxel in the management of early stage breast cancer

Therapeutic Nanoparticles for Drug Delivery in Cancer

Docetaxel for the adjuvant treatment of early nodepositive breast cancer: a single technology appraisal

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee

Shotgun proteomics of archival triple‐negative breast cancer samples

Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

Photopharmacology: Beyond Proof of Principle

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Targeting triple-negative breast cancer: optimising therapeutic outcomes

Selection of adjuvant chemotherapy for treatment of node-positive breast cancer

Adjuvant targeted therapy in early breast cancer